82366-44-7

Basic information

• Product Name: 4-fluoro-2,6-dinitroaniline
• CAS NO: 82366-44-7
• Molecular Formula: C₆H₄FN₃O₄
• Molecular Weight: 201.1121
• Mol File: 82366-44-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 364.3°C at 760 mmHg
• Flash Point: 174.1°C
• Density: 1.681g/cm³
• Vapor Pressure: 1.7E-05mmHg at 25°C
• Refractive Index: 1.649
• CAS DataBase Reference: 4-fluoro-2,6-dinitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-fluoro-2,6-dinitroaniline(82366-44-7)
• EPA Substance Registry System: 4-fluoro-2,6-dinitroaniline(82366-44-7)

Safety Data

• Hazardous Substances Data: 82366-44-7(Hazardous Substances Data)

Upstream product

• 342-49-4 2,6-dinitro-4-fluoroanisole 
• 371-41-5 4-Fluorophenol 
• 459-60-9 1-fluoro-4-methoxybenzene 
• 364-32-9 4-fluoro-2,6-dinitrophenol 
• 7308-45-4 4-fluoro-2,6-dinitro-phenol; potassium-compound 

Downstream Products

• 170098-85-8 1,2-diamino-4-fluoro-6-nitrobenzene 

Relevant articles and documents

A Synthetic Pathway to Substituted Benzofuroxans through the Intermediacy of Sulfonates: The Case Example of Fluoro-Nitrobenzofuroxans

Benzofuroxans are well known compounds that continue to attract particular attention since the discovery of 4,6-dinitrobenzofuroxan (DNBF) back in 1899. It has been shown that these compounds possess biological activities that are related to their electro

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.